Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence

NCT02962947 is registered in ClinicalTrials.gov with Azienda Sanitaria di Firenze as lead sponsor.

NCT NCT02962947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02962947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence
Lead sponsor
Azienda Sanitaria di Firenze
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 30, 2017
Completion date
June 30, 2022
Enrollment
546 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma